Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.

Carine Salliot; Claire Bombardier; Alain Saraux; Bernard Combe; Maxime Dougados

doi:10.1136/ard.2009.111179

Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 01 and/or 04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.

Carine Salliot ¹ Claire Bombardier ² Alain Saraux ^{3, 4} Bernard Combe ⁵ Maxime Dougados ⁶

1 Hôpital Lariboisière

2 IWH - Institute for Work and Health

3 EA2216 - Immunologie et Pathologie

4 CIC - Brest - Centre d'Investigation Clinique

5 IGMM - Institut de Génétique Moléculaire de Montpellier

6 Service de rhumatologie [CHU Cochin]

Abstract : OBJECTIVE: To assess the effect of reproductive factors, especially hormone replacement therapy (HRT) and its interaction with HLA-DRB1 *01 and/or *04 alleles on the diagnosis of rheumatoid arthritis (RA) and the presence of anti-cyclic citrullinated peptide (CCP) antibodies in women included in the ESPOIR cohort (early arthritis cohort). METHODS: 568 patients were included in the analyses, which were performed using logistic regression. RESULTS: HRT reduced the risk of RA due to the HLA-DRB1 *01 and/or *04 alleles from OR 1.88 (95% CI 1.32 to 2.68, p<0.000) for HLA-DRB1 *01 and/or *04 alleles alone to OR 1.07 (95% CI 0.51 to 2.26, p=0.85) in women with HLA-DRB1 *01 and/or *04 alleles who received HRT. One explanation might be the protective effect of HRT on the presence of anti-CCP antibodies (OR 0.43, 95% CI 0.24 to 0.77, p<0.006). Other reproductive factors such as the number of pregnancies, menopause and age at menopause, age at menarche and a history of pregnancy with poor outcome were not associated with the diagnosis of RA and the presence of anti-CCP antibodies. CONCLUSION: HRT may reduce the risk of RA due to HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP antibodies.

Type de document :

Article dans une revue

Annals of the Rheumatic Diseases, BMJ Publishing Group, 2010, 69 (9), pp.1683-6. 〈10.1136/ard.2009.111179〉

Domaine :

Sciences du Vivant [q-bio]

Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00930168
Contributeur : Ghislaine Calvez <>
Soumis le : mardi 14 janvier 2014 - 13:55:29
Dernière modification le : jeudi 11 janvier 2018 - 06:15:57

Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 01 and/or 04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Métriques

143

Contact

Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Partager

Métriques

143

Contact

Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 01 and/or 04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.